Here in this article, we take a good look at three upcoming Biotech Stocks, namely, InterMune, Advaxis, Inc & Amgen, Inc. InterMune Inc (NASDAQ ITMN) listed its shares as a big mover previous session, as its shares jumped over 35% after Roche AG’s declaration it would buy the respiratory-drug maker for $8.3B, in spite of…
SBA Communications SBAC notched another strong firstquarter result, highlighted by better-than-expected earnings and another guidance upgrade. First-quarter revenues grew by 62% year over year to $313 million–roughly 4% above consensus. The growth was driven by a 64.1% increase in the firm’s tower base, which now stands at 17,539. Once again, however, SBA’s growth was in…
Chinese Internet firm Sohu SOHU posted first-quarter revenue and earnings that slightly exceeded the firm’s guidance and our internal estimate, thanks to solid top-line growth across brand advertising, search, and gaming. Revenue grew by 36% year over year to $308 million (versus $299 million at the high end of guidance), while non-GAAP net income came…
Fed Chair Janet Yellen testified before the US Senate Committee on Banking, Housing, and Urban Affairs. She presented the Fed’s semiannual Monetary Policy Report (MPR) to the Congress. In her prepared remarks, she stated that while valuation seems “stretched” in some areas of the bond market, equities “remain generally in line with historical norms.” Yet…
Swedish consumer goods company Svenska Cellulosa reported first-quarter results that largely tracked our longerterm expectations. SCA’s hygiene operations (personal care and tissue) were once again steady performers while the forest product division lagged as a result of still-weak European demand for paper and solid-wood products. After reviewing the results, we are maintaining our fair value…
With second quarter earnings season coming to an end, focus in the biotech sector is back on pipeline and regulatory updates. Last week’s highlights included Achillion Pharmaceuticals, Inc.’s (ACHN) impressive interim data on its experimental hepatitis C virus (HCV) treatment, Gilead Sciences’ (GILD – Analyst Report) legal victory and Amgen’s (AMGN – Analyst Report) hit…
